METAVIA INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
METAVIA INC. (MTVA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $88.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-03-26
- METAVIA INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was $88.00K, a 87.23% increase from fiscal 2024.
- METAVIA INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2024 was $47.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2025-12-31 | $88.00K 10-K · filed 2026-03-26 |
| 2024-12-31 | $47.00K 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |